[Beta-blockaders in the treatment of arterial hypertension. Part I. Pharmacologic, hemodynamic and metabolic aspects].
D000319:Adrenergic beta-Antagonists / Q000145:classification / Q000378:metabolism / Q000627:therapeutic use*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D005110:Extracellular Space / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007678:Kidney Glomerulus / Q000187:drug effects; D009318:Natriuresis / Q000187:drug effects; D010280:Parathyroid Glands / Q000187:drug effects; D010281:Parathyroid Hormone / Q000502:physiology; D010758:Phosphorus / Q000378:metabolism; D010953:Plasma Volume / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D012083:Renin / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D010281:Parathyroid Hormone; D011943:Receptors, Adrenergic, beta; D010758:Phosphorus; D012083:Renin; D002118:Calcium
Les bêta-bloquants dans le traitement de l'hypertension artérielle. Ière partie: aspects pharmacologiques, hémodynamiques et métaboliques.